(1)
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively
Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x10
9 cells per infusion
Emergence of new T cell clones in the peripheral blood T cell repertoire four months after therapy was observed in patients analyzed from the highest dose level who experienced either a confirmed partial response or stable disease suggesting that modulation of the endogenous immune response may be an important mechanism of action of CYAD-101 in mCRC patients
email article
A sequential augmented reduced-intensity conditioning (RIC) regimen failed to improve post-transplant outcomes for patients with high-risk acute myeloid leukemia (AML) or myelodysplasia (MDS), a randomized trial showed.
Neither 2-year overall survival (OS) nor cumulative incidence of relapse improved as compared with standard RIC prior to allogeneic hematopoietic cell transplant (HCT). Detectable measurable residual disease (MRD) prior to transplant was associated with a twofold increase in relapse, but the data showed no evidence of interaction between MRD status and conditioning regimen, reported Charles Craddock, MD, of Queen Elizabeth Hospital in Birmingham, England, and co-authors in the In unrandomized phase II trials and retrospective registry data, the [intensified] protocol, which incorporates additional cytoreductive chemotherapy prior to a fludarabine-based RIC regimen, has been reported to reduce relapse and improve outcomes in high-risk AML or MD
Global T Lymphocyte Activation Antigen CD86 Market 2020 Industry Research, Segmentation, Key Players Analysis and Forecast to 2025 sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.